Comparison of the hypoglycemic effect of sitagliptin versus the combination of mitiglinide and voglibose in drug-naive Japanese patients with type 2 diabetes

被引:6
|
作者
Ohta, Akio [1 ]
Ohshige, Toshihiko [1 ]
Sakai, Kensuke [1 ]
Nakamura, Yuta [1 ]
Tenjin, Ayumi [1 ]
Tsukiyama, Shuichi [1 ]
Terashima, Yuko [1 ]
Matsubara, Fumiaki [1 ]
Kawata, Takehiro [1 ]
Nagai, Yoshio [1 ]
Tanaka, Yasushi [1 ]
机构
[1] St Marianna Univ, Sch Med, Div Endocrinol & Metab, Dept Internal Med,Miyamae Ku, Kawasaki, Kanagawa 2168511, Japan
关键词
1,5-anhydroglucitol; glycoalbumin; mitiglinide; sitagliptin; voglibose; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; ALPHA-GLUCOSIDASE INHIBITORS; FASTING PLASMA-GLUCOSE; FIXED-DOSE COMBINATION; INSULIN-SECRETION; POSTPRANDIAL HYPERGLYCEMIA; NATEGLINIDE; SULFONYLUREAS; RESISTANCE; RISK;
D O I
10.1517/14656566.2013.842554
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: The postprandial glucose (PPG) level is reduced by alpha-GIs, glinides and DPP4Is through different pharmacological actions. The aim of this study was to compare the effect of sitagliptin (S) versus that of the combination of mitiglinide and voglibose (M+V) on markers of glycemic control. Research design and methods: A randomized cross-over trial was performed in 20 patients with drug-naive type 2 diabetes. The patients were randomized to receive S (50 mg/day) or M+V (1 tablet 3 times daily). Treatment was continued for 8 weeks, after which they were switched to the other regimen and treated for another 8 weeks. At baseline, after the first regimen, and after the second regimen, a meal test was performed. Main outcome measures: The markers of glycemic control were examined. Results: Reduction of glucose excursion was significantly greater with M+V than with S. HbA(1c) did not change with either regimen. However, 1,5-anhydroglucitol showed a significant increase from baseline with both regimens (7.9 +/- 4.3 mu g/ml at baseline vs. 10.6 +/- 5.5 with S, p < 0.05 and 15.1 +/- 6.2 with M+V, p < 0.01). Compared with baseline, glycoalbumin was significantly reduced by M+V, but not S (19.6 +/- 2.9% at baseline vs. 17.3 +/- 3.8% with M+V, p < 0.05). Conclusion: M+V achieved better control of PPG excursion than S.
引用
收藏
页码:2315 / 2322
页数:8
相关论文
共 50 条
  • [21] REGULATION OF FREE FATTY ACID BY SITAGLIPTIN MONOTHERAPY IN DRUG-NAIVE SUBJECTS WITH TYPE 2 DIABETES
    Kutoh, Eiji
    Wada, Asuka
    Hayashi, Jyunka
    ENDOCRINE PRACTICE, 2018, 24 (12) : 1063 - 1072
  • [22] Adding the Combination Drug of Mitiglinide and Voglibose to Vildagliptin Results in Less Glucose Excursions than Adding Glimepiride in Patients with Type 2 Diabetes
    Fujimoto, Kanta
    Hamamoto, Yoshiyuki
    Honjo, Sachiko
    Yamaguchi, Eriko
    Shibayama, Yui
    Tokumoto, Shinsuke
    Koshiyama, Hiroyuki
    DIABETES, 2014, 63 : A284 - A284
  • [23] EFFECT OF MITIGLINIDE AND VOGLIBOSE, USED ALONE OR IN COMBINATION, ON DIURNAL GLUCOSE FLUCTUATIONS AND POSTPRANDIAL INSULIN SECRETION IN TYPE 2 DIABETES PATIENTS
    Taniguchi, Y.
    Mori, Y.
    Sezaki, K.
    Miyazaki, S.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2013, 15 : A33 - A33
  • [24] Efficacy and safety of gemigliptin/metformin initial combination therapy versus either as monotherapy in drug-naive patients with type 2 diabetes
    Lim, S.
    Min, K.
    Yu, J. -M.
    Chamnan, P.
    Kim, E.
    Yoon, K. -H.
    Kwon, S.
    Moon, M.
    Lee, K.
    Kim, D. -J.
    Kim, M.
    Wongtanate, M.
    Kim, E.
    Kim, S. -H.
    Lee, M. -K.
    DIABETOLOGIA, 2015, 58 : S54 - S54
  • [25] Effect of Combination Therapy with Alogliptin and Pioglitazone in Drug-Naive Patients with Type 2 Diabetes on β-Cell Function and Insulin Resistance
    Inzucchi, Silvio E.
    Rosenstock, Julio
    Seufert, Jochen
    Fleck, Penny
    Wilson, Craig
    Mekki, Qais
    DIABETES, 2009, 58 : A520 - A520
  • [26] Sitagliptin provides superior efficacy and tolerability compared to voglibose as monotherapy in Japanese patients with type 2 diabetes
    Iwamoto, Yasuhiko
    Ikadowaki, Takash
    Nonaka, Kenji
    Okamoto, Taro
    Okuyama, Kotoba
    Nishii, Mikio
    Stein, Peter P.
    DIABETES, 2008, 57 : A590 - A590
  • [27] A comparison of the effects of pioglitazone and gliclazide on metabolic control in drug-naive patients with type 2 diabetes
    Maher, L
    Edwards, G
    Lee, C
    Urquhart, R
    Johns, D
    Tan, M
    DIABETES, 2003, 52 : A461 - A461
  • [28] Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis
    Abe, Masanori
    Okada, Kazuyoshi
    Maruyama, Takashi
    Maruyama, Noriaki
    Matsumoto, Koichi
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (02) : 169 - 176
  • [29] Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naive Type 2 Diabetes
    Rosenstock, Julio
    Chuck, Leonard
    Gonzalez-Ortiz, Manuel
    Merton, Kate
    Craig, Jagriti
    Capuano, George
    Qiu, Rong
    DIABETES CARE, 2016, 39 (03) : 353 - 362
  • [30] Initial Combination Therapy with Metformin Plus Colesevelam in Drug-Naive Hispanic Patients with Early Type 2 Diabetes
    Rosenstock, Julio
    Hernandez-Triana, Eric
    Handelsman, Yehuda
    Misir, Soamnauth
    Jones, Michael R.
    Nagendran, Sukumar
    POSTGRADUATE MEDICINE, 2012, 124 (04) : 7 - 13